Avedro

Avedro is an ophthalmic pharmaceutical and medical device company that specializes in the treatment of corneal diseases and refractive conditions. The company is best known for developing the first and only FDA-approved corneal cross-linking (CXL) system, which utilizes the KXL System in conjunction with Photrexa (riboflavin 5’-phosphate ophthalmic solution). This therapeutic approach is designed to strengthen the cornea and halt the progression of keratoconus and corneal ectasia. Following its acquisition by Glaukos Corporation in 2019, Avedro's technology has become a cornerstone of Glaukos's corneal health franchise, with ongoing research into photorefractive intrastromal cross-linking (PiXL) for refractive correction.